Pre-market Hot Trades in US Stocks
Oklo is down 3.01% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 17, Oklo announced a partnership with Meta to develop a 1.2 gigawatt nuclear energy park and initiated the construction of its first commercial reactor at Idaho National Laboratory. This move boosted the company's stock price.
</li>
<li>
On April 17, Oklo's CEO emphasized the importance of nuclear energy in future space missions during an interview with CNBC, further increasing market attention on nuclear energy and driving up the stock price.
</li>
<li>
On April 19, Oklo's stock price rose 33.35% this week, as investors held an optimistic view on its nuclear energy applications in the space and defense sectors. The nuclear energy industry is supported by policy, and market attention has increased.
</li>
</ol>
Circle is down 3.01% in pre-market trading. Based on recent news:
<ol>
<li>
On April 17, Circle was accused of using its cross-chain transfer protocol, allowing attackers to transfer up to $230 million to the Ethereum blockchain. This lawsuit raised market concerns about Circle's security and management capabilities, leading to a drop in stock price.
</li>
<li>
On April 17, ARK Invest reduced its holdings by 11,465 shares of Circle stock, with a total value of approximately $1.215 million. This move was interpreted by the market as a lack of confidence in Circle's future performance, further pressuring the stock price.
</li>
<li>
On April 17, Circle announced the launch of its USDC Bridge service. Although this news indicates the company's technological progress, market concerns about its security and management capabilities remain dominant, failing to boost the stock price. Panic sentiment in the cryptocurrency market has eased, with significant capital inflow.
</li>
</ol>
Top Gainers in Pre-market US Stocks
Theriva Biologics is up 92.42% in pre-market trading. Based on recent key news:
<ol>
<li>
On April 17, Theriva Biologics announced that it would present additional data from the VIRAGE 2B clinical trial at the AACR 2026 annual meeting, involving the application of VCN-01 in metastatic pancreatic cancer. This news drove the stock price up, as investors increased their expectations for the new data.
</li>
<li>
On April 17, the company plans to conduct a low-dose study to test whether more frequent and extended VCN-01 administration can further improve outcomes. This move demonstrates the company's confidence in the efficacy of VCN-01, further boosting market sentiment.
</li>
<li>
On April 17, the poster data released by Theriva Biologics showed that the combination of VCN-01 with gemcitabine/nab-paclitaxel could improve overall survival and progression-free survival. This data enhanced market confidence in VCN-01, driving the stock price up. The biotechnology industry has been active recently, with significant capital inflow
Psyence Biomedical pre-market rose by 80.85%. Based on recent news,
</li>
<li>
On April 17, Psyence Biomedical announced that its pharmaceutical-grade psychedelic drug NPX-5 is entering clinical trials. The company's CEO stated that this expansion marks an important step in advancing NPX-5's clinical infrastructure, supporting ongoing patient dosing. This news drove the stock price up by 69.85%.
</li>
<li>
On April 18, U.S. President Trump signed an executive order to expedite the research and approval process for psychedelic therapies, focusing on drugs like ibogaine. This move aims to assist veterans suffering from severe mental illnesses, further boosting the stock price.
</li>
<li>
On April 19, Psyence Biomedical emphasized its fully integrated supply chain, capable of producing ibogaine at a commercial scale. This news sparked market discussions, and the stock price continued to rise. Changes in industry policies are accelerating research on psychedelic drugs.
</li>
</ol>
Fitness Champs pre-market rose by 79.35%. There has been no significant news recently; trading is active, and capital flows are evident. Considering sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news

OKLO

CRCL

Oklo pre-market down 3.01%; Circle pre-market down 3.01%; Theriva Biologics pre-market up 92.42%; Psyence Biomedical pre-market up 80.85%; Fitness Champs pre-market up 79.35%

Pre-market hot trades in US stocks: Oklo pre-market down 3.01%; Circle pre-market down 3.01%